Making a meaningful difference

Turning scientific innovation into meaningful impact

Zymeworks is a royalty-driven organization differentiated by in-house R&D capabilities developing novel medicines for patients with difficult-to-treat diseases. Through our proprietary platforms, deep scientific expertise, and global partnerships, we build and manage a portfolio of healthcare assets designed to deliver long-term impact across multiple therapeutic indications.

Partner with us

Integrating partnerships and collaborations is core to our business strategy and allows us to accelerate our efforts to bring novel therapeutics to the broadest group of patients.

News

March 18, 2026

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

March 17, 2026

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

March 2, 2026

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing